New Zealand Health Minister Denies Connection to Tobacco Industry

Sep.27.2024
New Zealand Health Minister Denies Connection to Tobacco Industry
New Zealand Health Minister Casey Costello strongly denies any ties to tobacco industry at health alliance meeting.

According to a report by MSN on September 27th, New Zealand's Deputy Health Minister Casey Costello strongly denied any connections with the tobacco industry at a health alliance meeting on Tuesday.


According to reports, at the meeting, Costello came under scrutiny from health researchers for loosening anti-smoking laws and providing a document titled "Nicotine is just as harmful as caffeine." The document also criticized the Labour Party's Smoke-Free Generation policy as being "nanny-state nonsense".


The minister recently reduced the consumption tax on heated tobacco products (HTP), making them a more attractive alternative to smoking. These changes align with the demands of tobacco companies, with the main player in the heated tobacco products market being Philip Morris International, which employs two former senior officials of the New Zealand First Party.


I have never had any association with the tobacco industry," Costello said in response to questioning of his credibility at the conference. "Despite extensive efforts, including the Freedom of Information Act and written parliamentary inquiries, no evidence has been found linking me to the tobacco industry, and I have never sought advice from them.


Costello added that according to documents obtained by the New Zealand Broadcasting Corporation under the Official Information Act, there is nothing in conflict with the policy positions of the New Zealand First Party.


Costello stated that the government is committed to achieving the Smoke-Free 2025 goal, which will require approximately 80,000 people to quit smoking by the end of next year to reach this target.


Due to the availability of alternatives such as e-cigarettes, many people have quit smoking. She also mentioned that legislation is being introduced to make smoking alternatives more affordable.


We need a set of appropriate legislation and regulatory systems to provide equal levels of regulation for smoking and other nicotine products.


She emphasized that the Smokefree 2025 goal is just the beginning. "We still need to remain vigilant to ensure that New Zealand remains smokefree, young people do not start smoking or using e-cigarettes, and those who have quit smoking or quit using e-cigarettes do not start again.


Chris Bullen, a tobacco researcher at the University of Auckland, is skeptical about New Zealand's ability to achieve its Smokefree 2025 goal. "I don't believe that the current plan will allow us to reach this goal, and it definitely cannot be achieved without significant costs," he said.


He also stated that repealing the smoke-free legislation is harmful, and believes that introducing new nicotine products into the market without testing is a radical experiment. However, he supports the government's efforts to improve regulation of smoking alternatives.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

BAT Japan to launch two new VELO nicotine pouch flavours in February
BAT Japan to launch two new VELO nicotine pouch flavours in February
BAT Japan will roll out two new VELO nicotine pouch variants from Feb. 2, 2026: Smooth Peppermint Medium and Breezy Mango Intense. The products will be sold via the official glo & VELO online store, the glo Store Ginza and nationwide tobacco retail channels in Japan.
Jan.23 by 2FIRSTS.ai
BAT CEO Says 2026 Return to Growth Hinges on U.S. Enforcement, Highlights Oral Leadership
BAT CEO Says 2026 Return to Growth Hinges on U.S. Enforcement, Highlights Oral Leadership
British American Tobacco said 2026 will mark a return to its mid-term growth algorithm, but CEO Tadeu Marroco stressed that deliverywill depend heavily on enforcement against illicit vapour products in the United States. Speaking at the FY2025 results call, he positioned Modern Oral as the company’s primary structural growth engine, reframed accelerating cigarette declines through “poly-usage,” and reinforced capital discipline with an expanded share buyback plan.
Feb.12
South Korea to regulate synthetic-nicotine e-liquids as tobacco from April 24
South Korea to regulate synthetic-nicotine e-liquids as tobacco from April 24
South Korea’s Health Ministry says amendments to the Tobacco Business Act will take effect on April 24, bringing synthetic-nicotine e-liquid vapes under the legal definition of tobacco. The shift extends cigarette-style rules to these products, including mandatory graphic warnings, sharply limited advertising channels, stricter vending-machine placement requirements, and a ban on use in smoke-free areas, with enforcement checks slated from late April.
Feb.03 by 2FIRSTS.ai
Indonesia’s Vape Excise Revenue Rises 7.38% in 2025 to $170.4M Amid Broader Tobacco Excise Decline
Indonesia’s Vape Excise Revenue Rises 7.38% in 2025 to $170.4M Amid Broader Tobacco Excise Decline
Indonesia’s customs data show vape (REL) excise revenue reached Rp 2.84 trillion in 2025 (≈$170.4 million), up 7.38% year over year. The gain came even as overall tobacco excise revenue declined. Minimum retail price benchmarks (HJE) for vape products rose in 2025, while excise rates remained unchanged from 2024; open-system e-liquids accounted for the largest share of revenue.
Jan.27 by 2FIRSTS.ai
Fourth Circuit weighs federal preemption challenge to North Carolina’s vape sales restrictions
Fourth Circuit weighs federal preemption challenge to North Carolina’s vape sales restrictions
Vape manufacturers and sellers urged the U.S. Court of Appeals for the Fourth Circuit to find that the federal Food, Drug, and Cosmetic Act (FDCA) preempts North Carolina’s new law restricting the sale of certain e-cigarette/ENDS products.
Feb.03 by 2FIRSTS.ai
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
A Fifth Circuit panel upheld the U.S. Food and Drug Administration’s 2021 final rule requiring companies seeking premarket authorization for new tobacco products to include information on health-risk investigations. In a published opinion, the court found FDA satisfied the Regulatory Flexibility Act’s procedural requirements and reasonably relied on the economic analysis from the 2016 “deeming rule” as a factual basis to certify limited impact on small businesses.
Feb.27 by 2FIRSTS.ai